סימבקסון 10

Country: Iżrael

Lingwa: Ebrajk

Sors: Ministry of Health

Ingredjent attiv:

SIMVASTATIN

Disponibbli minn:

DEXCEL PHARMA TECHNOLOGIES LTD

Kodiċi ATC:

C10AA01

Għamla farmaċewtika:

קפליות

Kompożizzjoni:

SIMVASTATIN 10 MG

Rotta amministrattiva:

פומי

Tip ta 'preskrizzjoni:

מרשם נדרש

Manifatturat minn:

DEXCEL LTD, ISRAEL

Grupp terapewtiku:

SIMVASTATIN

Żona terapewtika:

SIMVASTATIN

Indikazzjonijiet terapewtiċi:

Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvaxon is indicated to: - Reduce the risk of total mortality by reducing coronary death - Reduce the risk of non-fatal myocardial infarction - Reduce the risk for undergoing myocardial revascularization procedures - Reduce the risk of stroke and transient ischemic attacks (TIA's). Hyperlipidemia: Simvaxon is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvaxon therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hype

Sommarju tal-prodott:

Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Pravastatin, Simvastatin

Data ta 'l-awtorizzazzjoni:

2020-04-30